{"id":596747,"date":"2022-04-20T20:48:01","date_gmt":"2022-04-20T20:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=596747"},"modified":"2022-04-20T20:48:01","modified_gmt":"2022-04-20T20:48:01","slug":"primary-progressive-multiple-sclerosis-market-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-medday-pharma-medicinova-mapi-pharma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/primary-progressive-multiple-sclerosis-market-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-medday-pharma-medicinova-mapi-pharma-and-others_596747.html","title":{"rendered":"Primary Progressive Multiple Sclerosis Market Trends Analysis, Therapeutics Pipeline Outlook, and Epidemiology Insights 2032 | Key Companies &#8211; MedDay Pharma, MediciNova, Mapi Pharma, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Primary Progressive Multiple Sclerosis Market Trends Analysis, Therapeutics Pipeline Outlook, and Epidemiology Insights 2032 | Key Companies - MedDay Pharma, MediciNova, Mapi Pharma, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Primary Progressive Multiple Sclerosis Market Trends Analysis, Therapeutics Pipeline Outlook, and Epidemiology Insights 2032 | Key Companies - MedDay Pharma, MediciNova, Mapi Pharma, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Primary Progressive Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Progressive Multiple Sclerosis Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Primary Progressive Multiple Sclerosis market<\/strong> report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Primary Progressive Multiple Sclerosis Market \" src=\"https:\/\/www.abnewswire.com\/uploads\/b8d9a16108a81dd615b5fd37586a4ea1.jpg\" alt=\"Primary Progressive Multiple Sclerosis Market \" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Primary Progressive Multiple Sclerosis: An Overview<br \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><em>According to the National Multiple sclerosis Society, primary-progressive multiple sclerosis (PPMS) is a neurodegenerative disease that interferes with the brain&#8217;s ability to control the body. There are four main types of MS: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS. Each type might be mild, moderate, or severe. PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.<\/em><\/p>\n<p style=\"text-align: justify;\"><em>The occurrence and severity of Primary Progressive Multiple Sclerosis (PPMS) symptoms vary with each person. Symptoms include headaches, pain in the legs and feet, back pain, muscle spasms, trouble in walking, vision problems, etc. In addition, this condition affects men and women equally.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Primary Progressive Multiple Sclerosis Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>As per the National Multiple Sclerosis Society, about 15% of the total estimated MS patients in the United States with multiple sclerosis (MS) have the primary progressive form of the disease (PPMS).<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em><em>As per the estimates provided by Columbia University Medical Center (2018), on average, people with the primary progressive form of MS start having symptoms between ages 35 and 39.<\/em><\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>According to a study published by Schmidt et al. (2017), 84% of participants with PPMS were found to have an impaired sense of smell, compared with just 31% of those with relapsing-remitting MS.&nbsp;<\/em><em>As per a study conducted by the Houzen et al. (2017), titled &ldquo;Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan,&rdquo; out of all MS cases, only 2% of participants with MS were found to be primary progressive and established the relatively lower rates of progressive MS in northern Japan than in western countries.<\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/primary-progressive-multiple-sclerosis-ppms-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Primary Progressive Multiple Sclerosis Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Primary Progressive Multiple Sclerosis market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives complete detail of the <strong>Primary Progressive Multiple Sclerosis market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Primary Progressive Multiple Sclerosis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section covers insights into the historical and current <strong>Primary Progressive Multiple Sclerosis patient pool and forecasted trends<\/strong> for every seven major countries (7MM)&nbsp; from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Primary Progressive Multiple Sclerosis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Primary Progressive Multiple Sclerosis market<\/strong> or expected to get launched during the study period. The analysis covers Primary Progressive Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Primary Progressive Multiple Sclerosis Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/primary-progressive-multiple-sclerosis-ppms-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/primary-progressive-multiple-sclerosis-ppms-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Primary Progressive Multiple Sclerosis Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The Primary-progressive multiple sclerosis (PPMS) market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rise in the awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies during the forecast period.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Primary Progressive Multiple Sclerosis (PPMS) market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">MedDay Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MediciNova<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mapi Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Brainstorm-Cell Therapeutics&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Primary Progressive Multiple Sclerosis (PPMS) therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">GA Depot<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MN-166<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MD1003&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NurOwn<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/primary-progressive-multiple-sclerosis-ppms-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/primary-progressive-multiple-sclerosis-ppms-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Primary Progressive Multiple Sclerosis Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Primary Progressive Multiple Sclerosis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Primary Progressive Multiple Sclerosis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Primary Progressive Multiple Sclerosis Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Primary Progressive Multiple Sclerosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Primary Progressive Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Primary Progressive Multiple Sclerosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Primary Progressive Multiple Sclerosis Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Primary Progressive Multiple Sclerosis Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Primary Progressive Multiple Sclerosis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Primary Progressive Multiple Sclerosis Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Primary Progressive Multiple Sclerosis Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Primary Progressive Multiple Sclerosis Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Primary Progressive Multiple Sclerosis Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Primary Progressive Multiple Sclerosis Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Primary Progressive Multiple Sclerosis Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/primary-progressive-multiple-sclerosis-ppms-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/primary-progressive-multiple-sclerosis-ppms-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/food-allergy-market\">Food Allergy Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Food Allergy Market<\/strong>&rdquo; report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology, as well as the Food Allergy Market Trends in the 7MM. Some of the key companies in the Food Allergy Market include <em>Aimmune Therapeutics, Novartis, DBV Technologies, InnoUp Farma, Cour Pharmaceutical Development Company, Vedanta Biosciences, Regeneron Pharmaceuticals, Genentech, Rho Federal Systems Division, Alladapt Immunotherapeutics, Camallergy,<\/em> and Others.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=primary-progressive-multiple-sclerosis-market-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-medday-pharma-medicinova-mapi-pharma-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=primary-progressive-multiple-sclerosis-market-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-medday-pharma-medicinova-mapi-pharma-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Primary Progressive Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Progressive Multiple Sclerosis Market Size and Share &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/primary-progressive-multiple-sclerosis-market-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-medday-pharma-medicinova-mapi-pharma-and-others_596747.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-596747","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/596747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=596747"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/596747\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=596747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=596747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=596747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}